Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trappsol Cyclo in Niemann-Pick Disease Type C1
2024-518266-27-00Phase 3Authorised
- Sponsor
- Cyclo Therapeutics, Inc.
- Start
- Nov 2024
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial in Niemann-Pick disease type C1 (NPC1) comparing Trappsol Cyclo + standard of care with Placebo + standard of care (2 arms). Primary endpoints: Primary EU/RoW interim efficacy endpoint, Primary EU/RoW final efficacy endpoint and 2 more. Planned start Nov 2024; status: authorised.
02
Drugs
Trappsol Cyclo
03
Conditions
Niemann-Pick disease type C1 (NPC1)
Beyond the preview
Go deeper on 2024-518266-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518266-27-00.